Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR4 | P22455 | 13/20 | 0.50 |
| ▸ | EGFR | P00533 | 2/20 | 0.48 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.48 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.47 |
| ▸ | FGFR3 | P22607 | 3/20 | 0.47 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.47 |
| ▸ | BTK | Q06187 | 1/20 | 0.46 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CTSV | O60911 | 1/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16665334 | 0.85 | GCK (0.54) | FGFR4EGFRERBB2FGFR1FGFR3 | |
| SCHEMBL16665247 | 0.79 | FGFR4 (0.48) | FGFR4EGFRFGFR1FGFR3FGFR2 | |
| SCHEMBL16665246 | 0.79 | FGFR4 (0.56) | FGFR4FGFR1FGFR3FGFR2MAPK3 | |
| SCHEMBL16665335 | 0.79 | FGFR4 (0.59) | FGFR4FGFR1FGFR3FGFR2MAPK3 | |
| SCHEMBL16665266 | 0.78 | FGFR4 (0.54) | FGFR4EGFRFGFR1FGFR3FGFR2 | |
| SCHEMBL16665336 | 0.78 | FGFR4 (0.55) | FGFR4FGFR1FGFR3FGFR2MAPK3 | |
| SCHEMBL26697665 | 0.77 | MEN1 (0.59) | MEN1KMT2ACTSVCTSL | |
| SCHEMBL16665302 | 0.77 | MAPK3 (0.50) | FGFR4FGFR1FGFR3FGFR2MAPK3 | |
| SCHEMBL16665297 | 0.76 | MAPK3 (0.49) | FGFR4MAPK3 | |
| SCHEMBL16665248 | 0.76 | GCK (0.50) | FGFR4EGFRFGFR1FGFR3FGFR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015057963-A1 | FGFR4 INHIBITORS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-04-23 | — | — | WO | disclosed |
| US-20140107118-A1 | Novel Heterocyclic Derivatives and Their Use in the Treatment of Neurological Disorders | NOVARTIS AG (CH) | 2014-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140107118-A1 | Novel Heterocyclic Derivatives and Their Use in the Treatment of Neurological Disorders | BACE2, BACE1, PSEN2 | FGFR4 2244/4885EGFR 2424/4885ERBB2 621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.